Trending...
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- Beijing Review: ChASC5 Bridging Hearts Across The Pacific
- BMCC Tribeca PAC Presents New Season of Music, Theater & Family Fun
NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether 2seventy bio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 25, 2024, 2seventy bio issued a press release announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant." Explaining the decision, the Company's Chief Executive Officer cited "a greatly improved NDMM treatment landscape and . . . our rigorous review of the business case for the KarMMa-9 study".
More on Nyenta.com
On this news, 2seventy bio's stock price fell $0.45 per share, or 9.43%, to close at $4.32 per share trading on September 25, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
The investigation concerns whether 2seventy bio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On September 25, 2024, 2seventy bio issued a press release announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant." Explaining the decision, the Company's Chief Executive Officer cited "a greatly improved NDMM treatment landscape and . . . our rigorous review of the business case for the KarMMa-9 study".
More on Nyenta.com
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- Happi Coffee Launches with a Mission to Bring Freshness, Simplicity, and Intention to Your Daily Cup
- SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Krispy Kreme
- Local firm Launches QuickBooks Support to Help Small Businesses Streamline Finances and Boost Growth
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
On this news, 2seventy bio's stock price fell $0.45 per share, or 9.43%, to close at $4.32 per share trading on September 25, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- PR Brand Marketing Inc. Awarded GSA Multiple Award Schedule Contract with Strategic Support from Government Marketplace LLC
- LG GUGGENHEIM AWARD WINNER AYOUNG KIM OFFERS SNEAK PEAK INTO HER WORK PROCESS
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Interview with Dr. Eboni Ivory Green About Her New Book - Journey Beyond the Yellow Brick Road
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Yama Industrials Announces Next-Generation Data Analytics Platform
- Container Gardening eBook Launches Free "Recipe Designer" to End Common Potting Soil Mistakes
- Emmy-Winning Journalist José Martínez Releases Debut Book Your English is Great, But…
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Groupon, Inc. - GRPN
- BuggerCoin Blasts Off on Pump.Fun Ahead of $4B $PUMP ICO
- DimHum Announces Innovative Crowdshipping for USA, UK, Canada
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: HSON, ENZB, and BRZH
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Momentum Commerce Tracking of Amazon US Prime Day Sales Shows +165% Increase on Day 3, Path to Year-over-Year Growth
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Olson's Walk-Off Hit Gives N.L. All-Star Game Triumph In Strat-O-Matic Simulation
- Beijing Review: ChASC5 Bridging Hearts Across The Pacific